Skip to content

Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit

Single Visit Cervical Cancer Prevention Program

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00237562
Enrollment
Unknown
Registered
2005-10-12
Start date
1999-07-31
Completion date
Unknown
Last updated
2006-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Intraepithelial Neoplasia

Brief summary

1. Implement a single-visit program (SVP) for cervix cancer prevention in clinics serving a multi-ethnic population of women; 2. Set up an efficient system for interpretation of Pap smears for patients in the SVP that will minimize waiting time; 3. Determine the follow-up rates and compare them between women assigned to the SVP and a usual care program (UCP); 4. Determine satisfaction and compare it between women assigned to the SVP and the UCP; 5. Determine the cost-effectiveness and compare it between the SVP and UCP

Detailed description

Women were recruited from underserved communities to participate in this single visit cervix cancer project. Large loop electrosurgical excision procedure (LEEP) was performed on SVP subjects with either a diagnosis of HGSIL/AGUS or suspicion of carcinoma. All other subjects with abnormal Papanicolaou smears were referred to our abnormal cytology clinics or received care in the community.

Interventions

PROCEDURELarge loop electrosurgical excision

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of California, Irvine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Older than 18 years * No history of invasive cervical cancer * Not pregnant

Exclusion criteria

* Absence of a cervix * Abnormal vaginal bleeding * Cervical cancer screening within the previous 12 months * A known bleeding disorder * Reluctance to be randomized * Unwillingness to follow the study protocol

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 12, 2026